Grant Holder |
|---|
GIP ARRONAX Saint-Herblain, France |
GRANT HOLDER: Renaud DEVILDER |
Accountant: Laure PRIÉ |
Executive assistant: Céline HERAULT |
Management Committee & Core Group | |||
|---|---|---|---|
Action Chair | Dr Jean-François GESTIN | GIP ARRONAX, Nantes | France |
Vice Chair | Dr Emma ANEHEIM | University of Gothenburg | Sweden |
WG1 Leader | Dr Sture LINDEGREN | University of Gothenburg | Sweden |
WG2 Leader | Dr Joelle GASCHET | INSERM, Univ. of Nantes | France |
WG3 Leader | Dr Stig PALM | University of Gothenburg | Sweden |
WG4 Leader | Dr Jose Reinaldo CHICHARO DE FREITAS | FGUMA, Málaga | Spain |
WG5 Leader | Dr Dana NICULAE | IFIN-HH, Bucharest | Romania |
Science Communication Manager | Prof Emilija JANEVIK-IVANOVSKA | Goce Delcev University, Stip | North Macedonia |
SCM Co-Chair | Dr Laurent Navarro | Precerix | France |
STSM coordinator | Dr Marek PRUSZYNSKI | INCT, Warsaw | Poland |
STSM co-chair | Dr Petra Kolenc | Univ. Medical Centre Ljubljana | Slovenia |
ITC conference manager | Dr Penelope BOUZIOTIS | NCSR Demokritos, Athens | Greece |
ITC conference co-chair | Dr Andreas I. Jensen | Technical University of Denmark | Denmark |
Relation with Industry | Prof Antero ABRUNHOSA | Univ. of Coimbra/ICNAS | Portugal |
Relation with Industry | Dr Jean-François GESTIN | INSERM, Univ. of Nantes | France |
COST Association Administration | |
|---|---|
Science Officer | Dr Inga Dadeshidze |
Admin. Officer | Ms Jeannette NCHUNG ORU |
Description of Working Groups (WGs)
WG1
Astatine-211 targetry, production, extraction, back-up, logistics
Objective: To ensure reliable and sustainable astatine-211 production and development of a standardized purification method.
This WG will focus on astatine-211 production in order to ensure reliable access to inject patients with therapeutic doses of qualified astatine-211 within the ATNodes in Europe.
T.1.1. Establishing producer catalogue and astatine-211 production procedure;
T.1.2. Automating processes
T.1.3. Proposing alternative production solutions;
T.1.4. Researching the relevant intermediate (radiochemical) form(s) and final; (radiopharmaceutical) form for astatine-211 delivery;
T.1.5. Controlling stability, measuring radiolysis, defining present species;
T.1.6. Organising intra and extra cluster logistics / EU territorial grid / back-up.
WG2
Radiopharmaceuticals: development and preclinical Proof of Concept
Objective: Development of radiolabelling strategies adapted to different vectors.
This WG will focus on building different astatine-211 radiolabelled vectors in order to establish the preclinical proof of concept for some of them that will be pushed forward through the clinical development.
T.2.1. Setting up couples: vector / astatine-211:
– Innovating the design of more stable ligands;
– Developing modelling techniques confronted with physico-chemical measurements in order to optimize the astatine-211 ligand binding;
T.2.2. Setting up theranostic aspects: vector / imaging agents;
T.2.3. Sharing aspects of toxicology studies to prepare drug files;
T.2.4. Automating, optimizing and standardizing of radiolabelling protocols for clinical trials.
WG3
Improving Dosimetry for Optimizing Targeted Alpha Therapy with astatine-211
Objective: Construct and validate computer models for estimating absorbed dose to tumours and healthy tissues.
This WG will focus on dosimetry to predict efficacy and risks associated to the use of the different astatine derivates.
T.3.1. Collecting data on stability and biokinetics from all consortium members;
T.3.2. Constructing biokinetic models that provide the best fit to the collected data;
T.3.3. Proposing new experiments that will test/validate the new models;
T.3.4. Simulating decay of astatine-211 to the predicted distribution sites;
T.3.5. Generating (predicted) maps of absorbed dose to tumours and healthy tissues for a range of vector/astatine-211 combinations.
WG4
Clinical applications in Nuclear Medicine
Objective: Feedback and standardization of clinical practices.
This WG will focus on establishing which pathologies are best adapted to benefit from treatment with astatine-211 targeted therapy and prove the clinical potential. It will also focus on the organizational, regulation and economic aspects in order to evaluate the European practices and to propose a standardization of practices.
T.4.1. Identifying relevant pathologies for the use of astatine-211;
T.4.2. Analysing the practices of each member country and regulatory aspects;
T.4.3. Evaluating the cost of therapy in each member country;
T.4.4. Logistics and patient networking;
T.4.5. Assessing the issue of radioactive waste.
WG5
Valorisation of project results: exploitation, dissemination, communication
Objective: Make the technology visible and accessible to researchers, patients, EU practitioners and industrials.
This WG will focus on creating the conditions to leverage the barriers to the development of astatine-therapy by identifying therapeutical candidates and creating transfer and development conditions.
T.5.1. Identifying the exploitable results (patent potential check) and constituting patent application files;
T.5.2. Industrial transfer;
T.5.3. Dissemination of project results to relevant stakeholders;
T.5.4. Participating in existing lobbying groups;
T.5.5. Communicating to patients and practitioners;
T.5.6. Creating referent contacts for research and industry.
